SAGA

Sagaliam Acquisition Corp. Class A Common Stock

SAGA

Market cap $587M

Overview Fund Activity

Delisted

SAGA was delisted on the 7th of March, 2024.

Back to rankings

About: Sagaliam Acquisition Corp is a blank check company.

Employees: 3

Financials Shell Companies

Financial journalist opinion

SAGALIUM RESPONDS TO COMPETITOR'S FALSE AND MISLEADING PRESS RELEASE

BAYTOWN, TX, July 25, 2024 (GLOBE NEWSWIRE) -- Sagaliam Acquisition Corp (Expert Market: SAGA) (the “Company”) announced today that it believes that a misleading press release has been issued by Nika Pharmaceuticals, Inc. in another attempt by NIKA and its CEO, Dimtar Savov, to falsely claim rights to patents issued to Harry H. Zhabilov and the Zhabilov Trust for the Immunotherapy treatment of HIV/AIDS. Mr. Savov has erroneously and maliciously asserted claims to ITV-1 in attempts to mislead the investing public and to harm the shareholder value of SAGA as well as the former owner, Enzolytics, Inc. (PINK: ENZC). The exclusive license holder of this intellectual property is Virogentics, Inc., a wholly owned subsidiary of SAGA.

SAGALIUM RESPONDS TO COMPETITOR'S FALSE AND MISLEADING PRESS RELEASE

Sagaliam Acquisition Corp Launches Improved IPF Formula with Vitamin C in Pill and Lozenge Form and Addition of New Slimming Neutraceutical

BAYTOWN, TX / ACCESSWIRE / May 1, 2024 / Sagaliam Acquisition Corp ("SAGA", the "Company") (NASDAQ:SAGA) announced today that Virogentics, Inc., a wholly owned subsidiary of SAGA ("VIRO"), and the Bulgarian product development team, headed by Dr. Lachezar Ivanov and Harry Zhabilov, CSO, have developed a new IPF formula which combines a Vitamin C component with the existing patented compound. This product will be marketed as IPF Immune+ with Vit C.

Sagaliam Acquisition Corp Launches Improved IPF Formula with Vitamin C in Pill and Lozenge Form and Addition of New Slimming Neutraceutical

Saga Mainnet Arrives Today with Over 350 Projects

SAN FRANCISCO--(BUSINESS WIRE)-- #AI--Saga Mainnet Arrives Today with Over 350 Projects.

Saga Mainnet Arrives Today with Over 350 Projects

SAGALIAM ACQUISITION CORP. ANNOUNCES DELISTING OF COMMON SHARES FROM NASDAQ

New York, NY, March 07, 2024 (GLOBE NEWSWIRE) -- Sagaliam Acquisition Corp. (NASDAQ: “SAGAU”, “SAGA”, SAGAR”) (the “Company”) received a Nasdaq Hearing Withdrawal letter (“Notice”) from the Listing Qualifications staff of the Nasdaq Stock Market LLC (“Nasdaq”) on March 6, 2024.

SAGALIAM ACQUISITION CORP. ANNOUNCES DELISTING OF COMMON SHARES FROM NASDAQ

SAGALIAM ACQUISITION CORP. ANNOUNCES RECEIPT OF NASDAQ DELISTING LETTER - UPDATED

New York, NY, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Sagaliam Acquisition Corp. (NASDAQ: “SAGAU”, “SAGA”, SAGAR”) (the “Company”) received a delisting notification letter (“Notice”) from the Listing Qualifications staff of the Nasdaq Stock Market LLC (“Nasdaq”) on December 5, 2023.

SAGALIAM ACQUISITION CORP. ANNOUNCES RECEIPT OF NASDAQ DELISTING LETTER - UPDATED

SAGALIAM ACQUISITION CORP. ANNOUNCES RECEIPT OF NASDAQ DELISTING LETTER

New York, NY, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Sagaliam Acquisition Corp. (NASDAQ: “SAGAU”, “SAGA”, SAGAR”) (the “Company”) received a delisting notification letter (“Notice”) from the Listing Qualifications staff of the Nasdaq Stock Market LLC (“Nasdaq”) on December 8, 2023.

SAGALIAM ACQUISITION CORP. ANNOUNCES RECEIPT OF NASDAQ DELISTING LETTER

SAGALIAM ACQUISITION CORP. ANNOUNCES A TEMPORARY RESTRAINING ORDER ON ITS EXTENSION PROXY SHAREHOLDER MEETING

New York, NY, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Sagaliam Acquisition Corp. (NASDAQ: “SAGAU”, “SAGA”, “SAGAR”) (“we”, “us”, “our”, or the “Company”) announced today that it received a Temporary Restraining Order on its extension proxy shareholder meeting.

SAGALIAM ACQUISITION CORP. ANNOUNCES A TEMPORARY RESTRAINING ORDER ON ITS EXTENSION PROXY SHAREHOLDER MEETING

Enzolytics, Inc. Files Amended December 31, 2022 OTC Report with Audited Financials and Unaudited September 30, 2023 Quarterly Disclosure

Provides Updates on SAGA Transaction and on Virogentics, Inc. and Biogenysis, Inc. Progress ALLEN, TX / ACCESSWIRE / November 20, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/"https://enzolytics.com/). Enzolytics, Inc. (the "Company") filed an amended December 31, 2022 OTC Annual Report and its delinquent September 30, 2023 OTC quarterly disclosure.

Enzolytics, Inc. Files Amended December 31, 2022 OTC Report with Audited Financials and Unaudited September 30, 2023 Quarterly Disclosure

See News Rankings

Charts implemented using Lightweight Charts™